New York, USA - March 30, 2026 - Triple-negative breast cancer (TNBC) has long faced challenges in breast cancer research and drug development due to the lack of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. TNBC is highly heterogeneous and aggressive, which limits traditional targeted therapy and significantly increases the uncertainty of drug development in TNBC. In this context, Alfa Cytology optimizes its triple-negative breast cancer (TNBC) drug development laboratory while advancing animal models for breast cancer research to improve preclinical efficiency.
The drug development of TNBC involves multiple mechanisms, such as the DNA damage repair pathway, kinase signaling pathway, androgen receptor (AR), and tumor immunity. Relying on its professional triple-negative breast cancer (TNBC) drug development laboratory, Alfa Cytology supports multi-target and multi-strategy TNBC drug development research. A systematic research and development process was constructed from early target screening to mechanism analysis.
In this platform, Alfa Cytology integrates in vitro functional validation and mechanism studies to support the evaluation of candidate drugs at different stages of development and help researchers more efficiently screen potential therapies in the TNBC drug development laboratory. So as to deal with the complex molecular classification of triple-negative breast cancer.
To solve the problem of insufficient model transformation efficiency in TNBC research, Alfa Cytology further constructed a perfect animal model for the breast cancer research system. This system covers a variety of breast cancer animal models, such as CDX, PDX, and homologous transplantation, and is widely used in breast cancer research and TNBC preclinical verification studies.
Based on this animal models for breast cancer research platform, Alfa Cytology supports tumor growth monitoring, metastasis assessment, and tumor microenvironment analysis. For example, through the 4T1-LUC model system, the tumor metastasis process and immune response can be dynamically monitored, which provides key data support for the evaluation of the anti-tumor effect of TNBC drugs in vivo. At the same time, the platform also supports the research of combined treatment strategies, and further expands the research path of breast cancer research and TNBC drug development.
"In triple-negative breast cancer (TNBC) drug development, high-quality preclinical models are essential to evaluate therapeutic strategies," said a spokesperson from Alfa Cytology. "By integrating the TNBC drug development laboratory with the Animal models for breast cancer research platform, we are committed to providing researchers with more systematic and efficient support to accelerate the development and translation of innovative treatments."
About Alfa Cytology
Alfa Cytology specializes in preclinical research support for cancer research and innovative therapies. The company has established a triple-negative breast cancer (TNBC) drug development laboratory and animal models for a breast cancer research platform. By integrating advanced technologies, animal model resources, and expert teams, Alfa Cytology promotes breast cancer research and TNBC drug development while helping research institutions and biotech companies improve efficiency and translational outcomes.
Media Contact
Company Name: Alfa Cytology
Contact Person: Toya Davis
Email: Send Email
Country: United States
Website: https://breast-cancer.alfacytology.com
